BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALS

Introduction: Trials evaluating response-adapted use of radiotherapy (RT) in limited-stage Hodgkin lymphoma (LS-HL) have shown that the negative predictive value of PET is suboptimal. Additional biomarkers are needed to facilitate a risk-adapted approach. In the UK NCRI RAPID trial, baseline maximum tumour diameter (MTD) was associated with event-free survival (EFS) for LS-HL patients (pts) who achieved complete metabolic response (CMR; Illidge...